MeFOSAA: Understanding the Marker in PFAS Testing
MeFOSAA (Methylperfluorooctane sulfonamidoacetic acid) is one of the 9 specific PFAS (Forever Chemicals) measured in the PFAS (Forever Chemicals) 9 Panel by Quest Diagnostics. It is a chemical compound that belongs to the family of perfluorinated alkyl substances (PFAS), which are synthetic chemicals known for their resistance to heat, water, oil, and stains. These unique properties make PFAS useful in a wide range of consumer products, but their persistence in the environment and human body has raised concerns about potential health risks.
What is MeFOSAA?
MeFOSAA is a type of PFAS that contains a methyl group (-CH3) attached to a sulfonamidoacetic acid structure. It is part of a larger family of chemicals called perfluorooctane sulfonamides (PFOSA), which have been used in products such as water- and stain-resistant fabrics, fire-fighting foams, and nonstick cookware. MeFOSAA is one of the breakdown products of other PFAS chemicals, which means it can be present in the environment and in human bodies as a result of the degradation of more complex PFAS compounds.
Why is MeFOSAA Tested?
MeFOSAA is tested as part of the PFAS (Forever Chemicals) 9 Panel because it has been identified as one of the chemicals associated with potential health risks from PFAS exposure. While MeFOSAA is not as widely studied as other PFAS compounds, it is important to monitor its levels in the body, especially in individuals with known exposure to PFAS-containing products or environments.
Health Implications of MeFOSAA
Research into the health effects of MeFOSAA and other PFAS chemicals is ongoing, but there is evidence suggesting that exposure to high levels of PFAS may lead to various health concerns. Some potential risks associated with elevated MeFOSAA levels include:
-
Immune System Dysfunction: PFAS, including MeFOSAA, have been linked to reduced immune system function, making individuals more vulnerable to infections.
-
Cholesterol Imbalances: Elevated PFAS levels, including MeFOSAA, may be associated with unhealthy levels of cholesterol and other lipids in the blood, potentially increasing the risk of cardiovascular disease.
-
Developmental Concerns: High PFAS exposure has been linked to adverse effects on fetal and infant growth, potentially leading to developmental issues in children.
-
Cancer Risk: Some studies have suggested a link between PFAS exposure and certain types of cancer, such as kidney cancer, though more research is needed to fully understand the risks.
Why MeFOSAA is Important in PFAS Testing
MeFOSAA is included in the PFAS 9 Panel because it is a significant marker of PFAS exposure. By measuring MeFOSAA levels in the blood, healthcare providers can gain insight into a person’s overall exposure to PFAS and assess whether their levels fall within the typical range or are elevated. Elevated levels of MeFOSAA could signal long-term exposure to PFAS, which may increase the risk of the health concerns listed above.
Conclusion
MeFOSAA is a key PFAS marker included in the PFAS 9 Panel by Quest Diagnostics, providing important information about an individual’s exposure to these persistent chemicals. Monitoring MeFOSAA levels can help assess the potential health risks related to PFAS exposure. If your MeFOSAA result is elevated, it is important to discuss the findings with a healthcare provider to understand potential health implications and to take steps to minimize further exposure.
MeFOSAA
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.